B. Seifert
Sep 22, 2009
Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
von Moos R, Goldinger S, Michielin O, Schuller J, Gillessen Sommer S, Schlaeppi M, Cathomas R, Ochsenbein A, Seifert B, Dummer R (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). Presented at: ECCO / ESMO, Berlin
Sep 22, 2009Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
Sep 22, 2009ECCO / ESMO
von Moos Roger, Goldinger S., Michielin O., Schuller J.C., Gillessen Sommer Silke, Schlaeppi Marc, Cathomas R., Ochsenbein A., Seifert B., Dummer R.
more
Dec 2, 1994
Mutant p53 protein associated with chemosensitivity in breast cancer specimens (letter)
Hornung R, Koechli O, Schaer G, Seifert B, Haller U, Eppenberger U, Mueller H. Mutant p53 protein associated with chemosensitivity in breast cancer specimens (letter). Lacet 1994; 344:1647-1648.
Dec 2, 1994Mutant p53 protein associated with chemosensitivity in breast cancer specimens (letter)
Dec 2, 1994Lacet 1994; 344:1647-1648
Hornung René, Koechli O., Schaer G.N., Seifert B., Haller U., Eppenberger U., Mueller H.
more